

IN THE CLAIMS:

Please rewrite the pending claims as follows:

- <sup>1</sup>~~27~~. (currently amended) A method of treating cancer in a human comprising administering an amount of anticode oligomer effective for treating said cancer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary hybridizes to a translation initiation sequence of SEQ ID NO:19.
- <sup>2</sup>~~28~~. (previously presented) The method of claim <sup>1</sup>~~27~~, wherein said translation initiation sequence is ATG.
- <sup>3</sup>~~29~~. (previously presented) The method of claim <sup>1</sup>~~27~~, further comprising administering one or more chemotherapeutic agents.
- <sup>4</sup>~~30~~. (currently amended) A method of treating cancer in a human comprising administering an amount of anticode oligomer effective for treating said cancer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary hybridizes to a splice donor sequence of SEQ ID NO:19.
31. (previously presented) The method of claim 30, wherein said splice donor sequence is GT.
- <sup>5</sup>~~32~~. (previously presented) The method of claim <sup>4</sup>~~30~~, further comprising administering one or more chemotherapeutic agents.
- <sup>6</sup>~~33~~. (currently amended) A method of treating cancer in a human comprising administering an amount of anticode oligomer effective for treating said cancer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary hybridizes to a splice acceptor sequence of SEQ ID NO:19.
34. (previously presented) The method of claim 33, wherein said splice acceptor sequence is AG.
- <sup>7</sup>~~35~~. (previously presented) The method of claim <sup>6</sup>~~33~~, further comprising administering one or more chemotherapeutic agents.
- <sup>8</sup>~~36~~. (currently amended) A method of treating cancer in a human comprising administering an amount of anticode oligomer effective for treating said cancer, wherein said

anticode oligomer is from 10 to 40 bases in length and is complementary ~~hybridizes~~ to at least one codon of the first six codons of the open reading frame of SEQ ID NO:19.

9 ~~37~~ (previously presented) The method of claim ~~36~~<sup>8</sup>, further comprising administering one or more chemotherapeutic agents.

10 ~~38~~ (currently amended) A method of treating cancer in a human comprising administering an amount of anticode oligomer effective for treating said cancer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary ~~hybridizes~~ to the 5' cap region of SEQ ID NO:19.

11 ~~39~~ (previously presented) The method of claim ~~38~~<sup>10</sup>, further comprising administering one or more chemotherapeutic agents.

12 ~~40~~ (previously presented) The method as in any one of claims ~~28, 32, 35, 37~~<sup>3 5 7 9 11</sup> and ~~38~~ wherein the administration of said anticode oligomer and said one or more chemotherapeutic agents increases the sensitivity of said disorder or cancer to said one or more chemotherapeutic agents.

13 ~~41~~ (previously presented) The method as in any one of claims ~~27, 30, 33, 36~~<sup>1 4 6 8 10</sup> and ~~38~~, wherein said cancer is non-Hodgkin's lymphoma, prostate cancer, breast cancer, gastro-intestinal cancer or colon cancer.

14 ~~42~~ (currently amended) A pharmaceutical composition comprising an anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary ~~hybridizes~~ to a translation initiation sequence of SEQ ID NO:19, and a pharmaceutically acceptable carrier.

16 ~~43~~ (currently amended) A pharmaceutical composition comprising an anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary ~~hybridizes~~ to a splice donor sequence of SEQ ID NO:19, and a pharmaceutically acceptable carrier.

18 ~~44~~ (currently amended) A pharmaceutical composition comprising an anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary ~~hybridizes~~ to a splice acceptor sequence of SEQ ID NO:19, and a pharmaceutically acceptable carrier.

- <sup>20</sup>  
~~45.~~ (currently amended) A pharmaceutical composition comprising an anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary hybridizes to at least one codon of the first six codons of the open reading frame of SEQ ID NO:19, and a pharmaceutically acceptable carrier.
- <sup>22</sup>  
~~46.~~ (currently amended) A pharmaceutical composition comprising an anticode oligomer, wherein said anticode oligomer is from 10 to 40 bases in length and is complementary hybridizes to the 5' cap region of SEQ ID NO:19, and a pharmaceutically acceptable carrier.
- <sup>15</sup>  
~~47.~~ (previously presented) A method for increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising exposing said cell to the pharmaceutical composition of claim <sup>14</sup>~~42~~.
- <sup>17</sup>  
~~48.~~ (previously presented) A method for increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising exposing said cell to the pharmaceutical composition of claim <sup>16</sup>~~43~~.
- <sup>19</sup>  
~~49.~~ (previously presented) A method for increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising exposing said cell to the pharmaceutical composition of claim <sup>18</sup>~~44~~.
- <sup>21</sup>  
~~50.~~ (previously presented) A method for increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising exposing said cell to the pharmaceutical composition of claim <sup>20</sup>~~45~~.
- <sup>23</sup>  
~~51.~~ (previously presented) A method for increasing the sensitivity of a tumor cell to a chemotherapeutic agent, comprising exposing said cell to the pharmaceutical composition of claim <sup>22</sup>~~46~~.